Warning: The NCBI web site requires JavaScript to function. more...
Hemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration: a randomized cross-over trial comparing two hemofiltration rates.
Oudemans-van Straaten HM, van Schilfgaarde M, Molenaar PJ, Wester JP, Leyte A.
Crit Care. 2009;13(6):R193. Epub 2009 Dec 3.
Related citations
Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study.
de Pont AC, Oudemans-van Straaten HM, Roozendaal KJ, Zandstra DF.
Crit Care Med. 2000 Feb;28(2):421-5.
Citrate anticoagulation for continuous venovenous hemofiltration.
Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, van der Spoel JI, Dijksman LM, Zandstra DF.
Crit Care Med. 2009 Feb;37(2):545-52.
Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study.
Joannidis M, Kountchev J, Rauchenzauner M, Schusterschitz N, Ulmer H, Mayr A, Bellmann R.
Intensive Care Med. 2007 Sep;33(9):1571-9. Epub 2007 Jun 12.
Citrate compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients.
Janssen MJ, Deegens JK, Kapinga TH, Beukhof JR, Huijgens PC, van Loenen AC, van der Meulen J.
Kidney Int. 1996 Mar;49(3):806-13.
Dose effect relationship of reviparin in chronic hemodialysis: a crossover study versus nadroparin.
Reach I, Luong N, Chastang C, Chakroun M, Mirshahi S, Mirshahi MC, Soria J, Desmichels D, Baumelou A.
Artif Organs. 2001 Jul;25(7):591-5.
Predilution versus postdilution during continuous venovenous hemofiltration: a comparison of circuit thrombogenesis.
de Pont AC, Bouman CS, Bakhtiari K, Schaap MC, Nieuwland R, Sturk A, Hutten BA, de Jonge E, Vroom MB, Meijers JC, Büller HR.
ASAIO J. 2006 Jul-Aug;52(4):416-22.
The effects of continuous venovenous hemofiltration on coagulation activation.
Bouman CS, de Pont AC, Meijers JC, Bakhtiari K, Roem D, Zeerleder S, Wolbink G, Korevaar JC, Levi M, de Jonge E.
Crit Care. 2006;10(5):R150.
A randomized comparative crossover study to assess the affect on circuit life of varying pre-dilution volume associated with CVVH and CVVHDF.
Davies HT, Leslie G, Pereira SM, Webb SA.
Int J Artif Organs. 2008 Mar;31(3):221-7.
Anticoagulation with prostaglandin E1 and unfractionated heparin during continuous venovenous hemofiltration.
Kozek-Langenecker SA, Kettner SC, Oismueller C, Gonano C, Speiser W, Zimpfer M.
Crit Care Med. 1998 Jul;26(7):1208-12.
Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study.
de Pont AC, Hofstra JJ, Pik DR, Meijers JC, Schultz MJ.
Crit Care. 2007;11(5):R102.
Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs.
Jun L, Arnout J, Vanhove P, Dol F, Lormeau JC, Herbert JM, Collen D, Van de Werf F.
Coron Artery Dis. 1995 Mar;6(3):257-63.
Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study.
Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P.
Intensive Care Med. 2004 Feb;30(2):260-5. Epub 2003 Nov 5.
A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration.
Fealy N, Baldwin I, Johnstone M, Egi M, Bellomo R.
Int J Artif Organs. 2007 Apr;30(4):301-7.
[Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio].
Barata JD, Oliveira C, Bruges M, Gusmão L, Santana A, Ponce P, Simões J, Freire I, Crespo F, da Silva AN.
Acta Med Port. 1992 Feb;5(2):65-70. Portuguese.
Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration.
Heering P, Morgera S, Schmitz FJ, Schmitz G, Willers R, Schultheiss HP, Strauer BE, Grabensee B.
Intensive Care Med. 1997 Mar;23(3):288-96.
Comparative analysis of procoagulatory activity of haemodialysis, haemofiltration and haemodiafiltration with a polysulfone membrane (APS) and with different modes of enoxaparin anticoagulation.
Klingel R, Schaefer M, Schwarting A, Himmelsbach F, Altes U, Uhlenbusch-Körwer I, Hafner G.
Nephrol Dial Transplant. 2004 Jan;19(1):164-70.
Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers.
Azizi M, Veyssier-Belot C, Alhenc-Gelas M, Chatellier G, Billaud-Mesguish E, Fiessinger JN, Aiach M.
Br J Clin Pharmacol. 1995 Dec;40(6):577-84.
Continuous venovenous hemofiltration: an alternative to continuous arteriovenous hemofiltration and hemodiafiltration in acute renal failure.
Macias WL, Mueller BA, Scarim SK, Robinson M, Rudy DW.
Am J Kidney Dis. 1991 Oct;18(4):451-8.
Heparin clearance during continuous veno-venous haemofiltration.
Singer M, McNally T, Screaton G, Mackie I, Machin S, Cohen SL.
Intensive Care Med. 1994;20(3):212-5.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on